Alexis J. Gilman

Overview

Companies seeking antitrust clearance for their mergers and acquisitions, or that are parties or third parties in investigations and litigation launched by the Federal Trade Commission, the Antitrust Division of the Department of Justice, or state attorneys general, turn to Alexis Gilman for experienced and effective antitrust counsel. Alexis leverages years of experience at the FTC, including three years as head of a merger division, to represent clients in a broad range of antitrust and competition matters, including antitrust diligence and deal negotiations, merger reviews and clearances, government investigations, Hart-Scott-Rodino and foreign merger notifications, civil conduct matters, general antitrust compliance, trade association counseling, and antitrust litigation. Having advised clients that range from Fortune 100 firms to not-for-profit entities, his experience spans a wide range of industries, including healthcare, retail, consumer goods, food and beverage, technology products and services, distribution services, veterinary services, financial services, casinos and gaming, pharmaceuticals, biotechnology, digital health, and energy, among others. He has been recognized as a leading antitrust practitioner by Chambers USA, Who’s Who Legal/Global Competition Review, Lawdragon, Legal 500, and The Best Lawyers in America.

Alexisʼs practice has a particular focus on representing merging parties and third parties in merger investigations by the FTC, DOJ, and state attorneys general. He brings significant prior government experience and knowledge to his client work, having joined the firm after seven years at the FTC, where, as assistant director, he led the 30-attorney Mergers IV Division and worked on some of the agencyʼs highest-profile matters. While at the FTC, he had leading roles in and oversaw investigations and litigations in various industries, including hospitals and other healthcare providers, distribution services, retail, consumer goods, food and beverage, supermarkets, funeral homes, casinos, and online gaming. Prior to this position, he served as a deputy assistant director of the division from 2012 to 2014 and as a staff attorney in the division from 2010 to 2012.

Prior to joining the FTC, Alexis was an associate in the Antitrust Group of a large U.S.-based international law firm, where he represented Fortune 500 companies in U.S. and foreign merger investigations and other civil antitrust matters. He represented pharmaceutical, publishing, retail, chemical, energy, and private equity clients, among others.

Alexis is a frequent speaker at the ABA, American Health Law Association, and other organization events. He received his J.D. with honors from The George Washington University Law School, where he was a member of the George Washington International Law Review. He received his B.A. from Williams College. Alexis is originally from Maine.

Career & Education

|

Federal Trade Commission
Bureau of Competition, Mergers IV Division: Assistant Director, 2014–2017;
Deputy Assistant Director, 2012–2014;
Staff Attorney, 2010–2012
- Federal Trade Commission
  Bureau of Competition, Mergers IV Division: Assistant Director, 2014–2017;
  Deputy Assistant Director, 2012–2014;
  Staff Attorney, 2010–2012
Williams College, B.A., 1996
The George Washington University Law School, J.D., With Honors, 2002
- Williams College, B.A., 1996
- The George Washington University Law School, J.D., With Honors, 2002
District of Columbia
Massachusetts (Inactive)
- District of Columbia
- Massachusetts (Inactive)
Professional Activities and Memberships

Member of the American Bar Association and its Antitrust, Litigation, Business, and Health Law Sections

Member of The American Health Law Association and its Antitrust, Business Law and Governance, and In-House Counsel Practice Groups

Member of the Hispanic National Bar Association
Professional Activities and Memberships
- Member of the American Bar Association and its Antitrust, Litigation, Business, and Health Law Sections
- Member of The American Health Law Association and its Antitrust, Business Law and Governance, and In-House Counsel Practice Groups
- Member of the Hispanic National Bar Association

Alexis is a proven strategic leader with deep industry understanding and the ability to craft innovative solutions

— Chambers USA, 2024

Alexis's Insights

Speaking Engagement | 11.13.24

"Hot Topics in Antitrust for Life Sciences and Healthcare," Hispanic National Bar Association’s Health and Life Sciences Law Committee

Speaking Engagement | 11.08.24
"Part I: Hospital Mergers - Procedural Challenges and Developments," American Health Law Association
Press Coverage | 10.30.24
FTC Drills Down On Cross-Market Hospital Mergers
Client Alert | 8 min read | 10.15.24
FTC Significantly Curtails Long-Awaited Changes to HSR Premerger Notification Rules and Procedures

View All Insights

Representative Matters

Representing a brick-and-mortar and online food retailer in the FTC and state attorneys general investigation of and litigations challenging Kroger’s acquisition of Albertsons.
Representing multiple third parties in the FTC’s monopoly maintenance suit against Meta.
Represented Novant Health in the FTC’s investigation of and litigation challenging the proposed acquisition of two CHS hospitals, successfully defeating the agency’s motion for preliminary injunction in district court (transaction abandoned after injunction pending agency’s appeal).
Represented an advertising software firm in the FTC’s suit challenging IQVIA’s proposed acquisition of Propel Media.
Represented an integrated healthcare organization that was target of an FTC investigation of PBM contracting practices focused on insulin products (investigation concluded).
Represented multiple mortgage-industry firms as third parties in discovery in the FTC’s suit challenging the Intercontinental Exchange/Black Knight transaction.
Represented a technology company in the FTC’s Broadcom/VMware investigation.
Represented JAB and National Veterinary Associates in their concurrent $1.1 billion acquisition of SAGE Veterinary Centers and $1.6 billion acquisition of Ethos Veterinary Health (both cleared subject to consent orders).
Represented a technology company as a third party in the DOJ’s investigation of a wireless-technology transaction.
Represented a third party technology company in the FTC’s investigation and litigation of NVIDIA’s proposed acquisition of Arm Ltd.
Represented Dorel Industries in the sale of its Dorel Sports segment to Pon Holdings P.V. for $810 million.
Represented Novant Health in its $5 billion acquisition of New Hanover Regional Medical Center, the largest hospital acquisition in North Carolina history.
Represented NorthCrest Health in its sale to HCA’s TriStar Health.
Represented a veterinary-services provider in its acquisition of nearly 50 facilities from a multi-regional provider.
Represented Summa Health in its proposed affiliation with Beaumont Health (subsequently abandoned).
Represented a financial-services firm and its portfolio company in obtaining clearance from the FTC of an acquisition in an area subject to a Prior Notice requirement.
Represented a leading global manufacturer and marketer of branded consumer foods as a third party in the FTC’s merger investigation of the Post/TreeHouse Foods transaction.
Represented a marketer and seller of consumer products as a third party in the FTC’s investigation of the Altria/Juul transaction.
Represented a multinational Fortune 20 healthcare services company as a third party in the FTC’s conduct investigation and litigation against Vyera.
Represented AT&T in its successful defense of the DOJ’s suit challenging its $108 billion acquisition of Time Warner.
Represented a Fortune 100 healthcare services company as a third party in an FTC merger investigation.
Represented a grocery retailer as a third party in an FTC supermarket merger investigation.
Represented an office products distributor as a third party in an FTC office supplies merger investigation.
Counsel a national transportation-services provider and energy industry trade association on antitrust compliance issues.